Anhedonia in schizophrenia is a reduced ability to experience or pursue pleasure, and it affects a striking majority of people with the condition. Studies have found that 76 to 80 percent of schizophrenia patients show at least mild anhedonia, with roughly 23 to 60 percent experiencing marked or severe levels depending on how it’s measured. It belongs to a cluster of symptoms called “negative symptoms,” which involve the absence or reduction of normal functioning rather than the addition of unusual experiences like hallucinations.
How Anhedonia Fits Among Negative Symptoms
Schizophrenia symptoms fall into three broad categories: positive symptoms (hallucinations, delusions), cognitive symptoms (trouble with memory and attention), and negative symptoms (withdrawal, flat emotional expression, loss of motivation). The DSM-5 formally defines negative symptoms as “restricted emotional expression and avolition,” but it also recognizes anhedonia and social withdrawal as closely related features. In practice, anhedonia often overlaps with avolition, the loss of drive to start and follow through on activities. The two feed each other: when nothing feels rewarding, motivation drops, and when motivation drops, you stop doing things that might otherwise bring pleasure.
Two Types of Pleasure Loss
Researchers distinguish between two forms of anhedonia that don’t always travel together. Consummatory pleasure is the enjoyment you feel in the moment, like tasting a good meal or laughing at a joke. Anticipatory pleasure is the excitement or motivation you feel when looking forward to something rewarding.
For years, the prevailing view was that people with schizophrenia retain their ability to enjoy things in the moment but struggle with anticipatory pleasure. Multiple studies using a scale called the Temporal Experience of Pleasure Scale supported this: patients reported normal levels of in-the-moment enjoyment but reduced excitement about future events. Anticipatory anhedonia also correlated specifically with motivation and social withdrawal, suggesting it plays a bigger role in the day-to-day functional problems people face.
However, some research has pushed back on this neat division. At least one study found that both high-anhedonia and low-anhedonia patient groups reported significantly less consummatory pleasure than healthy controls, while anticipatory pleasure scores were virtually identical across all groups. The picture is likely more complex than a simple “wanting vs. liking” split, and the balance may vary from person to person.
What Happens in the Brain
The brain’s reward system relies heavily on a small region deep in the brain called the nucleus accumbens, part of the ventral striatum. This area lights up when you anticipate something good is about to happen, and dopamine is the main chemical messenger driving that signal. In both schizophrenia and depression, this region shows reduced activity during reward anticipation compared to healthy controls. A replicated neuroimaging finding confirmed that reduced signaling in the right nucleus accumbens is a hallmark of disrupted reward processing in both conditions.
The problem extends beyond a single brain region. Communication between the frontal cortex (involved in planning and decision-making) and the striatum (involved in reward processing) appears disrupted. Reduced activity in the orbitofrontal cortex and ventral striatum during reward anticipation correlates with greater anhedonia in schizophrenia patients. Dopamine signaling abnormalities are the most studied contributor, but disruptions in other chemical systems, including glutamate and serotonin, also play a role. Early life stress and chronic adversity can further dampen the reward circuitry, potentially worsening anhedonia over time.
How It Differs From Depression-Related Anhedonia
Anhedonia is a core feature of both schizophrenia and major depression, and the underlying brain changes overlap substantially. Both conditions involve reduced ventral striatum activity and disrupted communication in the same frontal reward networks. In neuroimaging studies, the two patient groups often look remarkably similar and don’t significantly differ from each other in reward-region activation.
The difference lies more in context than in biology. In depression, anhedonia tends to fluctuate with mood episodes and can improve substantially when the depressive episode lifts. In schizophrenia, anhedonia is typically more persistent and stable over time, embedded in the broader negative symptom picture alongside flat affect, reduced speech, and social withdrawal. It also interacts with cognitive difficulties that make it harder to remember past pleasures or mentally simulate future ones, compounding the motivational deficit in ways that go beyond low mood.
Real-World Impact on Daily Life
Anhedonia in schizophrenia isn’t just an internal experience of feeling less pleasure. It cascades into measurable life outcomes. A three-year follow-up study of people with social anhedonia (the specific loss of pleasure from relationships and social connection) found they were significantly less likely to be employed (62% vs. 81% of controls) and far more likely to drop out of college (17.7% vs. 2.5%). They reported fewer social supports and less satisfaction with the support they did have, and this gap actually widened over time relative to controls.
These aren’t small differences. The effect size for reduced social support was large, and the pattern held across employment, education, symptom burden, and mental health service use. People with social anhedonia also showed persistently elevated negative symptoms and poorer overall functioning at follow-up. One modestly encouraging finding: baseline family cohesion and social support were correlated with better functioning later on, suggesting that the social environment can buffer some of the impact.
Treatment Approaches
Anhedonia in schizophrenia is one of the harder symptoms to treat. Antipsychotic medications primarily target positive symptoms like hallucinations and delusions and generally do little for negative symptoms. Some may even worsen anhedonia by blunting dopamine signaling further.
Cognitive behavioral therapy produces modest reductions in negative symptoms, with treatment focusing specifically on reduced energy, motivation, pleasure, and diminished communication. A more targeted approach is behavioral activation, originally developed for depression but increasingly adapted for schizophrenia. The logic is straightforward: when people stop doing enjoyable activities, they lose the positive reinforcement that those activities provide, which makes them even less likely to engage in the future. Behavioral activation breaks this cycle through structured steps: monitoring daily activities, setting personal goals, planning activities that align with those goals, carrying them out, and identifying barriers along the way.
A version called motivational interviewing with behavioral activation combines these activity-scheduling techniques with conversations that help people connect with their own values and reasons for change. While the evidence base is still growing, the approach makes intuitive sense for anhedonia specifically because it doesn’t require someone to feel motivated before acting. Instead, it works from the outside in, reintroducing rewarding experiences that can gradually rebuild the connection between activity and pleasure.